Mesoblast (MESO) Tax Provisions (2017 - 2023)
Mesoblast (MESO) posted Tax Provisions of -$40000.0 for Q2 2023, up 13.04% sequentially from -$46000.0 in Q1 2023, and up 23.08% YoY from -$32500.0 in Q2 2022.
Mesoblast (MESO) Tax Provisions (2017 - 2023) Analysis & Trends
Mesoblast has reported Tax Provisions for 7 years, with the latest figure at -$40000.0 in Q2 2023.
- Quarterly Tax Provisions rose 23.08% year-over-year to -$40000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$212000.0 (up 11.3% YoY) and the FY2025 annual result came in at $330000.0, up 272.77% from the prior year.
- Tax Provisions improved to -$40000.0 in Q2 2023 per MESO's latest filing, from -$46000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $74000.0 in Q4 2020 and troughed at -$3.3 million in Q2 2020.
- A 5-year average of -$892500.0 and a median of -$75500.0 in 2021 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2019 and 2020: Tax Provisions slumped 211.17% in 2019, then surged 103.26% in 2020.
- Over 5 years, Tax Provisions stood at -$2.3 million in 2019, then soared by 103.26% to $74000.0 in 2020, then tumbled by 208.11% to -$80000.0 in 2021, then gained by 11.25% to -$71000.0 in 2022, then surged by 43.66% to -$40000.0 in 2023.
- According to Business Quant data, Tax Provisions over the past three periods registered -$40000.0, -$46000.0, and -$71000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -40,000.00 |
| Mar 31, 2023 | -46,000.00 |
| Dec 31, 2022 | -71,000.00 |
| Sep 30, 2022 | -55,000.00 |
| Jun 30, 2022 | -52,000.00 |
| Mar 31, 2022 | -45,000.00 |
| Dec 31, 2021 | -80,000.00 |
| Sep 30, 2021 | -62,000.00 |
| Jun 30, 2021 | -65,000.00 |
| Mar 31, 2021 | -98,000.00 |
| Dec 31, 2020 | 74,000.00 |
| Sep 30, 2020 | -730,000.00 |
| Jun 30, 2020 | -3.26 Mn |
| Mar 31, 2020 | -1.96 Mn |
| Dec 31, 2019 | -2.27 Mn |
| Sep 30, 2019 | -1.93 Mn |
| Jun 30, 2019 | -3.18 Mn |
| Mar 31, 2019 | -2.21 Mn |
| Dec 31, 2018 | -2.87 Mn |
| Sep 30, 2018 | -711,000.00 |